Tazemetostat: Preliminary Phase I/II data

Preliminary data from 47 evaluable relapsed or refractory NHL patients in the Phase II portion of an open-label, international Phase I/II trial showed that twice-daily 800 mg oral tazemetostat led to

Read the full 311 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE